Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M

Valeant Pharma (NYSE: VRX) reported GAAP Q1 EPS of $1.79, versus $1.08 reported last year. Revenue for the quarter came in at $2.11 billion, versus $2.37 billion reported last year.

• Adjusted EBITDA (non-GAAP) of $861 Million

2017 Guidance

2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75 billion from $3.55 - $3.70 billion

For earnings history and earnings-related data on Valeant Pharma (VRX) click here.

You May Also Be Interested In

• BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
• Korn Ferry to acquire AMS for about $1.1 billion